Tango Therapeutics
TNGX
58 hedge funds and large institutions have $741M invested in Tango Therapeutics in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 6 closing their positions.
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
26% more funds holding
Funds holding: 46 → 58 (+12)
2.57% more ownership
Funds ownership: 74.84% → 77.41% (+2.6%)
12% less capital invested
Capital invested by funds: $845M → $741M (-$104M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$12M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.2M |
| 3 |
Janus Henderson Group
London,
|
+$6.46M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.87M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$6.01M |
| 2 |
RI
RTW Investments
New York
|
-$5.04M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.61M |
| 4 |
BlackRock
New York
|
-$2.89M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$842K |
TNGX Hedge Fund Activity: Q4 2021 in Review
58 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q4 2021, worth a combined $741M — down 12% from $845M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TNGX positions and 6 closed out — a net gain of 12 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $12M. The largest seller was HHLR Advisors, cutting an estimated $6.01M.
- 58 institutional investors held Tango Therapeutics (TNGX) as of Q4 2021, up from 46 in Q3 2021.
- Funds reported $741M of Tango Therapeutics stock for Q4 2021, down 12% quarter-over-quarter.
- 18 funds opened new Tango Therapeutics positions in Q4 2021 and 6 closed out, a net change of +12 holders.
- The largest Tango Therapeutics buyer in Q4 2021 was Cormorant Asset Management, an estimated $12M added.
- The largest Tango Therapeutics seller in Q4 2021 was HHLR Advisors, an estimated $6.01M sold.
Based on aggregated 13F filings for Q4 2021.